IgE, best known for mediating allergic reactions, may also shape cancer outcomes. Learn how this immune molecule could serve as both a biomarker and a basis for next-generation therapies.

Immunovant remains a high-risk, high-reward play, hinging on the success of its next-gen candidate IMVT-1402. Click to read my latest analysis of IMVT stock.

A comprehensive study mapped the dynamic glycosylation landscape of rat serum proteins, uncovering sex- and time-dependent ...

Early broadly neutralising antibody responses against the E1E2 glycoprotein seem to be important for preventing persistence ...

Monoclonal antibodies (mAbs) contain N-linked glycans that influence pharmacokinetics and efficacy, making glycoform ...

Increased daily liveweight gain, respiratory health issues driven down by 75% and antibiotic use down 60% are the result of ...

Johnson & Johnson today announced findings from the Phase 2 DAHLIAS study published in The Lancet showing that nipocalimab, an investigational FcRn treatment for Sjögren's disease (SjD), significantly ...

A comprehensive study mapped the dynamic glycosylation landscape of rat serum proteins, uncovering sex- and time-dependent variations with clear ...

Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today presented positive topline data from Part 1 of ...

Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA) today announced that it will host a virtual event featuring two distinguished ...

Johnson & Johnson today announced plans to initiate the first head-to-head study comparing FcRn blockers for patients with generalized myasthenia gravis (gMG), which aims to affirm IMAAVYtm ...

IMM-529 IND: currently under review, FDA request for Information – minor updates to clinical protocol completed and submitted Travelan® P2TD ...